Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets
Neurosterix, which is reuniting some key figures behind Cobenfy, has corralled $105 million in a Series B to fund its lead schizophrenia candidate that hits one of the targets of Bristol Myers Squibb’s drug. The ...
Fred Callori, Neurosterix CEO November 11, 2026 04:00 PM EST FinancingStartups Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets Anna Brown News Reporter Neurosterix, which is reuniting some key figures behind Cobenfy, has corralled $105 million in a Series B to fund its lead schizophrenia candidate that hits … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that